drugset

drugset / Trial / NCT00633477

Efficacy and Safety of Resatorvid in Patients With Sepsis-induced Cardiovascular and Respiratory Failure

NCT00633477 ↗

Phase 3 Terminated 18 enrolled Takeda

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the effect of resatorvid on subjects with sepsis.

Timeline

Start: 2008-02
Primary completion: 2009-02
Completion: 2009-02

Outcome

Outcome not reported

Stopped (Business): “Business Decision; No Safety Or Efficacy Concerns.”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Resatorvid	Small molecule	2.4 mg/kg	—

Indications